ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

1541

Classifica tra le azioni #19093
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Prezzo delle azioni
$0.38168475
Capitalizzazione di mercato
$159.94M
Variazione (1 giorno)
-4.31%
Variazione (1 anno)
-70.34%
Paese
CN
Scambia ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)

Categoria

Healthcare
Storico del prezzo dell'azione per ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Prezzo di chiusura più alto: $0.40 il 2026-10-01

Prezzo di chiusura più basso: $3.27 il 2023-09-01
Storico del prezzo dell'azione di ImmuneOnco Biopharmaceuticals (Shanghai) Inc. dal 2023 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2026 (TTM) -25.34%
2025 11.64%
2024 -80.79%
2023 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$533.52 25.11%
US
$183.54 583.58%
US
$137.83 -3.78%
AU
$291.76 2.51%
BE
$887.97 9.06%
NL